Initial results from a clinical trial show that a drug called tolebrutinib can significantly slow down disability progression in people with secondary progressive MS who no longer experience relapses. The study recruited 1,131 participants with non-relapsing (non-active) secondary progressive MS. Participants were randomised with some taking tolebrutinib and others taking a placebo (a dummy drug) for up to […]
REFUEL-MS is an exciting research project developing an app-based treatment for MS-related fatigue using cognitive behavioural therapy (CBT), exercise and balance techniques. They have recently previewed the first version of the app. The content has been developed using the latest literature in close collaboration with experts from across the country, as well as those living with
National charity the MS Society is launching a Hospital Admissions Survey to explore the experiences of people with MS when attending the hospital. The survey asks about planned or unplanned (emergency) attendance and the reasons for it in order to gain an understanding of how and why MS patients are admitted to the hospital. The
ECTRIMS Patient Community Day is a day for people living with MS and related conditions to learn from top neurological experts about progress and updates being made in the treatment of their conditions. A roundtable panel of MS experts will discuss the latest progress being made in research, treatment and care – with a focus on trending
People living with MS in England, Wales and Northern Ireland who are currently receiving the drug ocrelizumab via an infusion can now be offered an injection that takes just ten minutes. Ocrelizumab is a disease modifying therapy (DMT) for active relapsing MS or early primary progressive MS. It can be taken as an intravenous infusion
Fatigue – an overwhelming tiredness – is one of the most common invisible symptoms of MS. For this webinar, you will be joined by the REFUEL-MS team. This is a research study that will draw together the current most effective cognitive-behavioural and exercise fatigue treatments into a tailored digital treatment that can be implemented routinely
Some interesting research is taking place into the benefits of table tennis for people with MS. A trial to scientifically validate table tennis treatment kicks off in the US and Italy this week, run by Dr Antonio Barbera, who has held regular table tennis sessions near Denver for three years and seen encouraging results. Dr
One of our members has recommended a 30 minute podcast which she thinks could be of interest. It’s an episode of Just One Thing with Michael Mosley and it’s an Inflammation Special with Janet Lord, who is Professor of Immune Cell Biology at the Institute for Inflammation and Ageing at Birmingham University. They talk about
You may have seen an interesting article about new scientific research on the BBC website recently. The genes which protected our ancestors from animal diseases now apparently raise the risk of MS. The researchers call their discovery “a quantum leap” in understanding the evolution of the condition and they say it could change opinions on
The MS Society has been sharing information on some recent research into the links between MS and the Epstein-Barr virus (EBV.) Last week, researchers from across the globe gathered together in Milan for ECTRIMS – the world’s largest MS research conference. Three new pieces of research were presented focusing on Epstein-Barr virus (EBV) – a common
